Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
British Journal of Dermatology2012Vol. 168(2), pp. 412–421
Citations Over TimeTop 1% of 2012 papers
Kim Papp, Richard G. Langley, Bárður Sigurgeirsson, Masatoshi Abe, Donald R Baker, Pille Konno, Sibylle Haemmerle, H.J. Thurston, C. Papavassilis, H. Richards
Abstract
Treatment with subcutaneous secukinumab 3 × 75 mg and 3 × 150 mg met the primary outcome of PASI 75 response achievement after 12 weeks, demonstrating efficacy in moderate-to-severe psoriasis.
Related Papers
- → Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis(2019)12 cited
- → Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authors(2018)1 cited
- → 26248 Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: Results from the EXCEED study(2021)1 cited
- → Cost-utility of secukinumab in Italian patients with moderate to severe plaque-type psoriasis(2017)
- → Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis(2020)